TG Therapeutics, Inc.
787 Seventh Avenue
48th Floor
New York
New York
10019
United States
Tel: 212-554-4484
Fax: 212-554-4531
Website: http://www.tgtherapeutics.com/
Email: ir@tgtxinc.com
402 articles about TG Therapeutics, Inc.
-
The U.S. Food and Drug Administration announced they are investigating a possible death risk for TG Therapeutics’ Ukoniq (umbralisib).
-
The studies are of the U2 combination Ukoniq (umbralisib) and ublituximab for chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).
-
TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor Conference
1/24/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities’ 2022 Virtual Oncology Investor Conference, taking place on Thursday, January 27, 2022, at 10:00 AM ET.
-
TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
TG Therapeutics, Inc., announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference.
-
TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million$70 million funded at closing
1/4/2022
TG Therapeutics, Inc., announced that its existing term loan facility agreement with Hercules Capital, Inc., has been amended to increase the size of the facility to $200 million, with $70 million funded at closing.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
12/14/2021
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis (RMS).
-
TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
12/14/2021
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two data presentations, highlighted data from the UNITY-CLL Phase 3 trial evaluating the combination of ublituximab and UKONIQ (umbralisib), the Company’s inhibitor of PI3K-delta and CK1-epsilon, (U2).
-
TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting
12/13/2021
TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting.
-
TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 63rd American Society of Hematology (ASH) Annual Meeting
12/10/2021
TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of data presentations at the upcoming 63 rd American Society of Hematology (ASH) annual meeting and exposition, to be held December 11 – 14, 2021, virtually and also live at the Georgia World Congress Center in Atlanta, Georgia.
-
TG Therapeutics Provides Regulatory Update Company to host conference call today, Tuesday, November 30, 2021 at 8:30 AM ET
11/30/2021
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has notified the Company that it plans to host a meeting of the Oncologic Drugs Advisory Committee (ODAC) in connection with its review of the pending Biologics License Application (BLA).
-
TG Therapeutics to Participate in the Jefferies London Healthcare ConferenceFireside chat available for on demand download at 5:00 PM GMT/ 3:00 AM ET on Thursday November 18, 2021
11/15/2021
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies London Healthcare Conference, taking place virtually November 18 – 19, 2021.
-
TG Therapeutics to Participate in the B. Riley Securities Fall 2021 Growth Biotech Best Ideas Virtual Series Fireside chat scheduled for 12:00 PM ET on Thursday November 11, 2021
11/9/2021
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities’ Fall 2021 Growth Biotech Best Ideas Virtual Series, taking place on Thursday November 11, 2021, at 12:00 PM ET.
-
TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
11/4/2021
TG Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2021 and recent company developments, along with a business outlook for the remainder of 2021.
-
TG Therapeutics Highlights Data Selected for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
11/4/2021
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the release of six abstracts that will be presented at the upcoming 63rd American Society of Hematology (ASH) annual meeting and exposition, to be held December 11 – 14, 2021, virtually and also live at the Georgia World Congress Center in Atlanta, Georgia
-
TG Therapeutics to Host Conference Call on Third Quarter 2021 Financial Results and Business UpdateConference call to be held Thursday, November 4, 2021 at 8:30 AM ET
11/1/2021
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Thursday, November 4, 2021 at 8:30 AM ET to discuss results for the third quarter 2021 and provide a business outlook for the Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look. -
TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
10/14/2021
TG Therapeutics, Inc. today announced data presentations, including additional analyses from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab, the Company’s investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide, in patients with relapsing forms of multiple sclerosis (RMS).
-
TG Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
9/30/2021
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis (RMS).
-
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
9/29/2021
The ULTIMATE I & II Phase 3 trials both have met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period